Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    Journal Title:  Blood Primary Author:  Itzykson ... cytogenetics , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) ...

    Research Article last updated 07/28/2014 - 8:53am.

  2. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... Five of these patients had an ongoing requirement for red blood cell transfusions despite previous treatment with recombinant ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    Journal Title:  J Blood Med Primary Author:  Abou ... of patients with del(5q) MDS, including reduction in red blood cell transfusion requirements and improvements in quality of ...

    Research Article last updated 03/02/2015 - 2:11pm.

  4. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

    ... catheter placement (ORadj=6.47, 95% CI: 2.37, 17.62) and red blood cell transfusion (ORadj=4.60, 95% CI: 2.29, 9.23) were associated ...

    Research Article last updated 12/05/2011 - 10:09am.

  5. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... mg at 16 weeks, respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were ...

    Research Article last updated 07/29/2014 - 12:12pm.

  6. Myelodysplastic syndromes and the role of iron overload.

    ... in patients with MDS due to the long-term use of red blood cell transfusions in patients with symptomatic anemia . ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... Lenalidomide (LEN) has been shown to yield red blood cell (RBC) transfusion independence in about 25% of lower ...

    Research Article last updated 04/24/2012 - 2:47pm.

  8. Therapy for aplastic anemia

    ... in the unrelated donor registry, including cord blood. He is red cell- and platelet transfusion -dependent. He has been recommended ...

    Research Article last updated 01/09/2012 - 10:58am.

  9. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... more and longer haematological responses and increased red blood cell transfusion independence . Azacitidine prolonged overall ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Costs and quality of life in patients with myelodysplastic syndromes.

    Journal Title:  Am J Blood Res Primary Author:  ... most MDS patients become anaemic, so as to require red blood cell transfusions. To investigate the costs and the impact on ...

    Research Article last updated 09/16/2013 - 8:45am.